Matches in Wikidata for { <http://www.wikidata.org/entity/Q92088240> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q92088240 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q92088240 description "scientific article published on 01 April 2019" @default.
- Q92088240 description "wetenschappelijk artikel" @default.
- Q92088240 description "наукова стаття, опублікована 1 квітня 2019" @default.
- Q92088240 name "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 name "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 type Item @default.
- Q92088240 label "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 label "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 prefLabel "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 prefLabel "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 P1433 Q92088240-EFEA60A3-16B4-4B0A-B20D-31F6C0F2D966 @default.
- Q92088240 P1476 Q92088240-FFFBCC70-18C5-4864-8B89-A6BCC9E81E24 @default.
- Q92088240 P2093 Q92088240-03BEAE03-C9D8-42FA-AE71-9507B814EF42 @default.
- Q92088240 P2093 Q92088240-343AD777-F5EA-4EB0-9D5C-52619D791DB1 @default.
- Q92088240 P2093 Q92088240-497ABDD0-CF25-44A5-B118-654B8366E7FF @default.
- Q92088240 P2093 Q92088240-4D54184F-4C5B-4F83-A21A-8D5C872A5E17 @default.
- Q92088240 P2093 Q92088240-7E069984-736C-4AB3-9909-F2E56E857BEB @default.
- Q92088240 P2093 Q92088240-8E02A3A2-031C-427D-9FEC-42D3E60DB1F1 @default.
- Q92088240 P2093 Q92088240-B7FAD1E1-0F2D-4B9A-9899-82FF54F75954 @default.
- Q92088240 P2093 Q92088240-F5E46115-62B2-4051-8359-184FD08D5861 @default.
- Q92088240 P304 Q92088240-9162FD5B-CA2B-4411-84DB-0B097A0F2255 @default.
- Q92088240 P31 Q92088240-C239A2FA-41B4-4CFD-936A-9F5C3AC1EBA2 @default.
- Q92088240 P356 Q92088240-E664EDF9-2444-4850-86D6-C535F73F5B86 @default.
- Q92088240 P433 Q92088240-21D670B3-3629-490F-9FCA-10FB1EB03319 @default.
- Q92088240 P478 Q92088240-9E361A69-AFFA-465A-835F-6205C0FF11D6 @default.
- Q92088240 P577 Q92088240-1BF38EC9-44BA-411F-89A0-E1EDA4D8D28D @default.
- Q92088240 P698 Q92088240-EAFDE2A6-FCCA-483F-B9A5-C929A1C04F1A @default.
- Q92088240 P921 Q92088240-01EC887C-B6C3-458A-BAA7-E1C69AC4E77C @default.
- Q92088240 P921 Q92088240-B019F251-A086-4727-8604-91D5C61C0DF9 @default.
- Q92088240 P356 J.CLGC.2019.03.019 @default.
- Q92088240 P698 31097390 @default.
- Q92088240 P1433 Q332266 @default.
- Q92088240 P1476 "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder" @default.
- Q92088240 P2093 "Chester Kao" @default.
- Q92088240 P2093 "Chris Alley" @default.
- Q92088240 P2093 "Jason Zhu" @default.
- Q92088240 P2093 "Megan McNamara" @default.
- Q92088240 P2093 "Neil Spector" @default.
- Q92088240 P2093 "Rajan T Gupta" @default.
- Q92088240 P2093 "Shekeab Jauhari" @default.
- Q92088240 P2093 "Tian Zhang" @default.
- Q92088240 P304 "e672-e677" @default.
- Q92088240 P31 Q13442814 @default.
- Q92088240 P356 "10.1016/J.CLGC.2019.03.019" @default.
- Q92088240 P433 "3" @default.
- Q92088240 P478 "17" @default.
- Q92088240 P577 "2019-04-01T00:00:00Z" @default.
- Q92088240 P698 "31097390" @default.
- Q92088240 P921 Q13896859 @default.
- Q92088240 P921 Q18975728 @default.